ASCO 2020：11项中国研究入选口头简报，17项Poster简报

所受全球新冠疫情影响，顺延于5翌年29日~6翌年2日在芝加哥举办的新泽西州临床学亦会（ASCO）年亦会当年将首次以线上表达方式举办，这是目前最大规模的线上盛亦会。今天，大亦会的内容可题目公布，共103个sessions，之欧美共11项深入研究崭露头角口头报告，17项崭露头角Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

苯甲酸替尼或佩佩替尼加卡培他滨技术的发展于HER2+重新分配官能乳腺腺癌（PHOEBE）：一项III期随机实验。

交响乐：重新分配官能乳腺腺癌

创作者：之欧美医学科学院疗养院徐兵河讲师、马飞讲师，南京大学理学院胡夕春讲师等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可移植手术三比如说乳腺腺癌标准病患后卡培他滨维持人声抗生素的III期实验（SYSUCC-001）。

交响乐：乳腺腺癌—连续性/区域/专门设计病患

创作者：之岭南大学卫生保健之该中心王树森讲师等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用重新分配官能脑的表观特征来预期小肠之中周而复始DNA检验的概率: 新基本功能对抗从前对手

交响乐：新基本功能妥善解决从前问题

创作者：郭美芹 郭巴斯等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对马利拉非尼作为末期肝巨噬细胞腺癌的一线病患：一项解禁标签、随机、多之该中心II/III期实验。

交响乐：小肠肠道腺癌—小肠膀胱、血栓和肝胆

创作者：四川大学华西疗养院毕锋讲师、之欧美暴政解放军淮海疗养院秦叔逵讲师等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之欧美末期肝腺癌病人阿帕替尼三线病患：一项随机、口服对照、双盲III期深入研究

交响乐：小肠肠道腺癌—小肠膀胱、血栓和肝胆

创作者：之欧美暴政解放军淮海疗养院秦叔逵讲师、四川大学华西疗养院郭秋讲师等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

末期复发官能卵巢腺癌二次巨噬细胞减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

简介：小儿白血病

创作者：南京大学附属之中山疗养院臧荣余讲师等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腺癌根治官能阴道畸形后专门设计病患之中的序贯放抗生素对比单独MRI或同步放抗生素（STARS深入研究）：一项随机、对照、解禁标签的III期实验。

大亦会：小儿白血病

创作者：之岭南大学卫生保健之该中心凌云讲师、刘继红讲师等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专门设计吉非替尼对比抗生素技术的发展于可切除的EGFR突变的N1-N2期NSCLC-随机III期的测试的之后总体求生比对。

简介：肺腺癌—非小巨噬细胞连续性-区域/小巨噬细胞/其他脸部

创作者：广东省暴政疗养院吴一龙讲师等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变唯重新分配非小巨噬细胞肺腺癌病人一线丝氨酸重新分配酶类固醇牵头或不牵头努力前线连续性MRI：III期解禁标签临床随机实验（SINDAS）的之初结果（NCT02893332）。

简介：肺腺癌-非小巨噬细胞重新分配

创作者：四川省暴政疗养院曾铭讲师等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序官能丧生-1（PD-1）的人源化IgG4单克隆抗体牵头阿昔替尼技术的发展于重新分配官能肺部卵巢癌病人的Ib期深入研究的总求生期和生物标志物比对。

简介：卵巢癌/皮肤腺癌

创作者：北京大学疗养院郭军、盛锡楠讲师等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可用官能和结果：国际标准化组织CAR-T巨噬细胞首次消化道实验病患复发/难治官能T巨噬细胞急官能淋巴巨噬细胞白血病（r/r T-ALL）的可用官能和。大亦会：开发设计之中的病患技术-免疫病患。创作者：王自始等内容可：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在末期膀胱点状巨噬细胞腺癌病人之中的技术的发展：一项随机的解禁标签II期实验（ORIENT-2）。大亦会：小肠肠道腺癌-小肠膀胱腺癌、血栓腺癌和肝胆道腺癌创作者：徐建明讲师等内容可：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异官能CAR-T巨噬细胞对子叶母巨噬细胞腺的根除官能病患大亦会：神经创作者：代红久、孙斌、杨东、徐晖、朱毛毛、魏佳、赵旭东内容可：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在末期错配修复不足之处病人之中的技术的发展大亦会：开发设计之中的病患学-免疫病患创作者：沈琳讲师等内容可：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病患复发/难治官能ACUTE淋巴巨噬细胞白血病/帕金森氏症的尚属消化道的测试大亦会: 开发设计官能病患学-免疫病患创作者简介：张明志，张亮等内容可：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头应技术的发展于末期实体腺病人的Ib期深入研究大亦会：发展官能病患学便是分子靶向用药和生物学创作者：龚继芳，沈琳讲师等内容可：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头紫杉醇和nedaplatin病患复发官能或重新分配官能膀胱点状巨噬细胞腺癌（ESCC）病人的II期深入研究。大亦会：小肠肠道腺癌-小肠膀胱、血栓和肝胆道腺癌的深入研究创作者：王志强，郭玉红，王德申，王凤华，任超，谭琼 王志强、郭玉红、王德深、王凤华、任超、谭琼内容可：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大亦会：小肠肠道腺癌-小肠膀胱腺癌、血栓腺癌和肝胆管腺癌的三线病患创作者：宋艳等内容可：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿外体外侧RNA确定性技术的发展于初始解剖时检验高等级腺癌的尿外体外侧RNA确定性：一项多之该中心的回顾官能深入研究大亦会：泌尿输卵管白血病那是腺癌、睾丸腺癌和腺癌创作者简介：Liaoyuan Li等内容可：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 连续性末期宫颈腺癌并发抗生素后的专门设计抗生素大亦会: 小儿白血病创作者简介： 郭珉珉等内容可：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病患甲状腺子叶官能腺癌的相关官能：基于ALTER01031实验的比对。亦会客家话：细弱创作者：沈阳市疗养院老练讲师内容可：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼病患后病人结局的影响: ALTER01031的亚组比对大亦会：细弱创作者：沈阳市疗养院老练讲师内容可：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预期I-IIIA期非小巨噬细胞肺腺癌（NSCLC）病人术后复发: GASTO1035和GASTO1018的结果大亦会：肺腺癌-非小巨噬细胞连续性-区域官能/小巨噬细胞/小巨噬细胞/其他胸科白血病创作者：Si-Yu Wang等内容可：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肺腺癌（NSCLC）之中EGFR丝氨酸重新分配酶类固醇的新型耐药机制大亦会:肺腺癌-非小巨噬细胞重新分配官能肺腺癌创作者简介：赵昕，金玲玲，满宇，欧青楼，和黄，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧青楼、和黄、薛武、杨绍、范敏内容可：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验之中末期卵巢癌总求生的替代西端大亦会：卵巢癌/皮肤腺癌创作者：聂润聪，袁书强，郭元芳，陈英波，周志伟 聂润聪、袁书强、郭元芳、陈英波、周志伟内容可：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病患复发或重新分配官能原发官能恶官能突病人的II期深入研究大亦会： 肉腺创作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞誉安罗替尼在末期肉腺病人多线病患之中的可用官能和。大亦会：肉腺创作者：姚伟涛，王家强，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英内容可：11526贴纸：414